Liraglutide explained: what TikTok gets right and wrong

What did @endocrinologiaemdia actually say?

Honestly? It is nearly impossible to tell. The transcript attributed to this video is incoherent, reading like a garbled auto-translation or a speech-recognition failure applied to Portuguese audio. There are no identifiable medical claims about liraglutide in the text provided. The caption promises information for people already using liraglutide, but the transcript delivers nothing clinically specific.

Given the account name and category tag, the video almost certainly discussed liraglutide as a GLP-1 receptor agonist. But fact-checking requires actual claims, and this transcript provides none. What follows is grounded in what an endocrinology educator would typically cover about liraglutide, cross-referenced against current evidence, not fabricated claims from a broken transcript.

Does the science back this up?

Liraglutide has a solid but increasingly dated evidence base. It works, but newer GLP-1 agents have largely outperformed it in head-to-head comparisons. That context matters if you are choosing a therapy.

The SCALE Obesity and Prediabetes trial (Davies et al., 2015, New England Journal of Medicine) showed that 3 mg daily liraglutide produced roughly 8 percent body weight loss versus about 2.6 percent with placebo over 56 weeks. That is real, clinically meaningful weight loss, but semaglutide 2.4 mg in the STEP 1 trial (Wilding et al., 2021, NEJM) produced about 14.9 percent. Tirzepatide in SURMOUNT-1 (Jastreboff et al., 2022, NEJM) hit up to 20.9 percent. Liraglutide still has strong cardiovascular outcome data from the LEADER trial (Marso et al., 2016, NEJM), showing reduced major adverse cardiovascular events in type 2 diabetes. That evidence base matters clinically.

What did they get wrong (or right)?

We cannot fairly assign errors to a creator when their transcript is unreadable. What we can say is that the category framing, liraglutide as a GLP-1 receptor agonist for weight management and type 2 diabetes, is accurate. Liraglutide is FDA-approved under the brand name Victoza for type 2 diabetes and as Saxenda at the higher 3 mg dose for chronic weight management.

Common errors in liraglutide content online include overstating its weight loss magnitude compared to semaglutide, understating gastrointestinal side effects (which affect up to 40 percent of users per the SCALE trials), and failing to mention that daily injections are required rather than the once-weekly dosing of semaglutide or tirzepatide. If the video made those errors, they would be misleading to an audience already on the medication. Without a readable transcript, we cannot confirm or deny it.

What should you actually know?

If you are using liraglutide right now, here is what the evidence says you should understand. Liraglutide mimics the GLP-1 hormone, slowing gastric emptying and increasing insulin secretion in a glucose-dependent way. It does not cause hypoglycemia on its own unless combined with insulin or sulfonylureas.

Nausea is the most common reason people discontinue it. Starting at 0.6 mg daily and titrating slowly over several weeks reduces, but does not eliminate, that risk. Pancreatitis is a labeled warning, though the absolute risk remains low based on post-marketing data. There is a rodent-model association with medullary thyroid carcinoma, which is why liraglutide carries a boxed warning and should not be used in people with a personal or family history of MTC or MEN2. These are not scare tactics. They are things your prescribing clinician should have discussed with you before you started.

The bigger picture on GLP-1 content online

TikTok endocrinology content varies wildly in quality. Accounts run by credentialed clinicians can genuinely help patients understand their medications. The problem is that even well-intentioned creators sometimes oversimplify side effect profiles, skip contraindications, or fail to contextualize where a drug sits in the current treatment landscape.

Liraglutide is not obsolete, but it is no longer the first-line GLP-1 choice for most people seeking weight loss, given the superior efficacy of semaglutide and tirzepatide. A video that does not address that comparison is leaving viewers with an incomplete picture. If you are on liraglutide because of cost, formulary access, or tolerability reasons, that is a legitimate clinical decision. If you are on it because your provider has not revisited your regimen recently, that conversation might be worth having.